Accelerate Diagnostics, Inc. (AXDX)
NASDAQ: AXDX · Real-Time Price · USD
1.160
-0.030 (-2.52%)
Dec 20, 2024, 4:00 PM EST - Market closed

Company Description

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East.

The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.

The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012.

Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Accelerate Diagnostics, Inc.
Accelerate Diagnostics logo
Country United States
Founded 1982
IPO Date Nov 18, 1996
Industry Medical Devices
Sector Healthcare
Employees 134
CEO Jack Phillips

Contact Details

Address:
3950 South Country Club Road, Suite 470
Tucson, Arizona 85714
United States
Phone 520 365 3100
Website acceleratediagnostics.com

Stock Details

Ticker Symbol AXDX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000727207
CUSIP Number 00430H102
ISIN Number US00430H2013
Employer ID 84-1072256
SIC Code 3826

Key Executives

Name Position
Jack Phillips Chief Executive Officer, President and Director
David Patience Chief Financial Officer
Lawrence Michael Mertz Chief Technology Officer
Maya Gowri Senior Vice President and Head of Operations
John Meduri Chief Strategy Officer
Chris Thode Senior Vice President of US Commercial
Rita Boukamel Senior Vice President and Head of EMEA

Latest SEC Filings

Date Type Title
Dec 5, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 10-Q Quarterly Report
Nov 7, 2024 8-K Current Report
Sep 30, 2024 8-K Current Report
Aug 26, 2024 8-K Current Report
Aug 12, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report
Aug 8, 2024 8-K Current Report